Entry note
JD: Healthcare and biotech catalyst desk
Watches obesity drugs, healthcare leaders, trials, and defensive growth. JD.com is back near $447.95, so the desk marked it as actionable. If price loses $427.79, the idea gets downgraded quickly.
$447.95Entry
$427.79Risk rule
$472.59Focus